Ionis Pharmaceuticals, Inc.

726 articles with Ionis Pharmaceuticals, Inc.

• Ionis reports first quarter 2019 financial results

  5/9/2019

  Ionis Pharmaceuticals, Inc. reported its financial results for the first quarter of 2019 and recent business highlights.

• Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients

  5/6/2019

  Ionis Pharmaceuticals, Inc. unveiled its new corporate brand in a campaign inspired by its unique culture and history of developing transformative therapies for seemingly untreatable diseases.

• Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases

  5/1/2019

  Twelve presentations highlighting transformational medicines for SMA, hATTR, Huntington's disease, ALS, prion disease and others

• Ionis Pharmaceuticals to hold first quarter 2019 financial results webcast

  4/25/2019

  Webcast scheduled for Thursday, May 9th at 11:30 a.m. Eastern Time

• Ionis Pharmaceuticals to Provide Corporate Update at 2019 Annual Meeting of Stockholders

  4/8/2019

  Ionis Pharmaceuticals, Inc. announced that management will present a general corporate update in conjunction with its 2019 Annual Meeting of Stockholders and Open House on Thursday, June 6 at 2:10 p.m. Pacific Time in Carlsbad, CA.

• Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors

  3/25/2019

  Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, announced that Brett P. Monia, Ph.D., has been appointed to the company's board of directors.

• 

  BioSpace's Global Biopharma Roundup: March 7

  3/7/2019

  Biotech and pharma companies from across the globe share data and news in a weekly roundup.

• PTC to Expand Product Portfolio in Latin America with WAYLIVRA™

  3/4/2019

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive opinion for WAYLIVRA™ by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA

• Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)

  3/1/2019

  Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending conditional marketing authorization for WAYLIVRA

• Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome

  2/28/2019

  Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced the company’s support for Rare Disease Day 2019 for patients living with hereditary transthyretin (hATTR) amyloidosis and familial chylomicronemia syndrome (FCS) and their caregivers, including bringing several of them together to participate in a live panel discussion related to their disease.

• Ionis Exceeds 2018 Financial Guidance

  2/27/2019

  Ionis Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year 2018 and reviewed highlights of its successful year.

• AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License

  2/25/2019

  Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that Novartis has exercised its option to license AKCEA-APO(a)-LRx, a drug to treat patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease (CVD). AKCEA-APO(a)-LRx, referred to by Novartis as TQJ230, was discovered by Ionis and co-developed by Akcea and Ionis.

• Ionis Pharmaceuticals to Hold 2018 Financial Results Webcast

  2/13/2019

  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 27th at 11:30 a.m. Eastern Time to discuss its 2018 financial results and report on pipeline and business progress.

• First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease

  1/28/2019

  First of 4+ Ionis programs expected to advance to pivotal studies this year

• Ionis Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference

  1/2/2019

  Ionis Pharmaceuticals, Inc. today announced that Management will present a Company overview at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 4:00 p.m. PT in San Francisco, CA.

• Ionis Announces Plans for Management Transitions in 2020

  12/20/2018

  Ionis Pharmaceuticals, Inc. and its Board of Directors announced today that, effective January 2020, Ionis' founder and CEO, Stanley T. Crooke, M.D., Ph.D., will be transitioning from chief executive officer to executive chairman of Ionis' board of directors.

• First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting

  11/27/2018

  Wholly-owned LICA drug for beta-thalassemia, IONIS-TMPRSS6-L Rx, demonstrates therapeutic potential with positive modulation of important disease-related biomarkers and increase of serum hepcidin in initial clinical study

• Ionis Pharmaceuticals to Present at Jefferies 2018 London Healthcare Conference

  11/13/2018

  Ionis Pharmaceuticals, Inc. today announced that management will present a company overview at the Jefferies 2018 London Healthcare Conference.

• Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions

  11/12/2018

  Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), were presented in a late-breaking clinical trial presentation at the American Heart Association Scientific Sessions in Chicago November 10, 2018.

• Ionis Pharmaceuticals to Host Investor Day

  11/9/2018

  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will host an Investor Day on Friday, December 7th at 7:30 a.m. Eastern Time at Marriott East Side in New York, NY.